Education
About Us
Working with TipRanks
Follow Us
Guardian Pharmacy Services, Inc. Class A (GRDN)
NYSE:GRDN
GRDN Stock Chart & Stats
$33.51
$0.47(2.39%)
At close: 4:00 PM EST
$33.51
$0.47(2.39%)
Day’s Range― - ―
52-Week Range$17.78 - $37.43
Previous Close$20.98
Volume93.63K
Average Volume (3M)348.83K
Market Cap
$2.12B
Enterprise Value$2.12B
Total Cash (Recent Filing)$36.49M
Total Debt (Recent Filing)$34.08M
Price to Earnings (P/E)52.6
Beta0.62
Next Earnings
Mar 11, 2026EPS Estimate
0.27Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.25
Shares Outstanding36,253,742
10 Day Avg. Volume450,542
30 Day Avg. Volume348,833
Financial Highlights & Ratios
PEG Ratio0.03
Price to Book (P/B)8.81
Price to Sales (P/S)1.02
P/FCF Ratio30.20
Enterprise Value/Market Cap1.00
Enterprise Value/Revenue1.53
Enterprise Value/Gross Profit7.73
Enterprise Value/Ebitda25.80
Forecast
1Y Price Target
$35.50Price Target Upside5.94% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
EPS Forecast (FY)1.13
Revenue Forecast (FY)$1.42B
Bulls Say, Bears Say
Bulls Say
Revenue GrowthGuardian's strong revenue growth, fueled by organic expansion and acquisitions, indicates robust market demand and effective business strategies.
Strategic AcquisitionsStrategic acquisitions in new regions enhance Guardian's market position and growth potential, supporting long-term revenue and market share expansion.
Cash GenerationStrong cash generation provides financial flexibility, enabling Guardian to invest in growth opportunities and manage potential financial challenges.
Bears Say
High LeverageSignificant leverage without equity raises concerns about financial stability and limits the company's ability to absorb economic shocks.
Operational InefficienciesInefficiencies impacting profitability suggest potential challenges in cost management and operational execution, affecting long-term margins.
Regulatory ChallengesRegulatory uncertainties can disrupt operations and increase compliance costs, posing risks to Guardian's strategic execution and profitability.
Guardian Pharmacy Services, Inc. Class A News
GRDN FAQ
What was Guardian Pharmacy Services, Inc. Class A’s price range in the past 12 months?
Guardian Pharmacy Services, Inc. Class A lowest stock price was $17.78 and its highest was $37.43 in the past 12 months.
What is Guardian Pharmacy Services, Inc. Class A’s market cap?
Guardian Pharmacy Services, Inc. Class A’s market cap is $2.12B.
When is Guardian Pharmacy Services, Inc. Class A’s upcoming earnings report date?
Guardian Pharmacy Services, Inc. Class A’s upcoming earnings report date is Mar 11, 2026 which is in 8 days.
How were Guardian Pharmacy Services, Inc. Class A’s earnings last quarter?
Guardian Pharmacy Services, Inc. Class A released its earnings results on Nov 10, 2025. The company reported $0.25 earnings per share for the quarter, beating the consensus estimate of $0.235 by $0.015.
Is Guardian Pharmacy Services, Inc. Class A overvalued?
According to Wall Street analysts Guardian Pharmacy Services, Inc. Class A’s price is currently Undervalued.
Does Guardian Pharmacy Services, Inc. Class A pay dividends?
Guardian Pharmacy Services, Inc. Class A does not currently pay dividends.
What is Guardian Pharmacy Services, Inc. Class A’s EPS estimate?
Guardian Pharmacy Services, Inc. Class A’s EPS estimate is 0.27.
How many shares outstanding does Guardian Pharmacy Services, Inc. Class A have?
Guardian Pharmacy Services, Inc. Class A has 36,253,742 shares outstanding.
What happened to Guardian Pharmacy Services, Inc. Class A’s price movement after its last earnings report?
Guardian Pharmacy Services, Inc. Class A reported an EPS of $0.25 in its last earnings report, beating expectations of $0.235. Following the earnings report the stock price went up 5.042%.
Which hedge fund is a major shareholder of Guardian Pharmacy Services, Inc. Class A?
Currently, no hedge funds are holding shares in GRDN
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Guardian Pharmacy Services, Inc. Class A Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$35.50 (5.94% Upside)
$35.50 (5.94% Upside)
Hedge Fund Trend
Decreased
By 81.9K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $99.8K over
the Last 3 Months
the Last 3 Months
Technicals
SMA
Positive
20 days / 200 days
Momentum
28.50%
12-Months-Change
Fundamentals
Return on Equity
25.85%
Trailing 12-Months
Asset Growth
12.07%
Trailing 12-Months
Company Description
Guardian Pharmacy Services, Inc. Class A
Guardian Pharmacy Services, Inc., a pharmacy service company, provides a suite of technology-enabled services designed to help residents of long-term health care facilities (LTCFs) in the United States. Its individualized clinical, drug dispensing, and administration capabilities are used to serve the needs of residents in lower acuity LTCFs, such as assisted living facilities and behavioral health facilities and group homes. The company's Guardian Compass includes dashboards created using data from its data warehouse to help its local pharmacies plan, track, and optimize their business operations; and GuardianShield Programs for LTCFs. The company was founded in 2003 and is based in Atlanta, Georgia.
GRDN Earnings Call
Q3 2025
0:00 / 0:00
Earnings Call Sentiment|Neutral
Guardian Pharmacy reported strong financial growth and increased guidance for the year, driven by successful acquisitions and organic growth. However, regulatory challenges and the dilutive impact of recent acquisitions present ongoing challenges. The positive financial performance and strategic expansions are tempered by these operational and external pressures.View all GRDN earnings summariesGRDN Stock 12 Month Forecast
Average Price Target
$35.50
▲(5.94% Upside)
Technical Analysis
Ownership Overview
Currently, No data available
---